These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 19122260)

  • 1. [New development in bisphosphonate treatment. Fracture prevention by bisphosphonates].
    Hosoi T
    Clin Calcium; 2009 Jan; 19(1):11-8. PubMed ID: 19122260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New development in bisphosphonate treatment. When and how long should patients take bisphosphonates for osteoporosis?].
    Yamaguchi T; Sugimoto T
    Clin Calcium; 2009 Jan; 19(1):38-43. PubMed ID: 19122263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Alendronate for treatment of osteoporoses].
    Harada A
    Nihon Rinsho; 2009 May; 67(5):943-7. PubMed ID: 19432114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates].
    Okazaki R
    Clin Calcium; 2009 Jan; 19(1):30-6. PubMed ID: 19122262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A-TOP research group/JOINT program].
    Kuroda T; Miyakawa N; Miyazaki T; Shiraki M
    Nihon Rinsho; 2009 May; 67(5):1017-21. PubMed ID: 19432126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New development in bisphosphonate treatment. Clinical significance of combinatorial therapies with bisphosphonates and parathyroid hormone for osteoporosis].
    Takeuchi Y
    Clin Calcium; 2009 Jan; 19(1):85-90. PubMed ID: 19122268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT) - 02.
    Orimo H; Nakamura T; Fukunaga M; Ohta H; Hosoi T; Uemura Y; Kuroda T; Miyakawa N; Ohashi Y; Shiraki M;
    Curr Med Res Opin; 2011 Jun; 27(6):1273-84. PubMed ID: 21554143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Daily practice using the guidelines for prevention and treatment of osteoporosis. Evolution of bisphosphonate therapy. Intravenous injection].
    Hagino H; Hashimoto J; Okano T; Katagiri H
    Clin Calcium; 2008 Aug; 18(8):1176-82. PubMed ID: 18677057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Role of pharmaceutical intervention in the treatment of osteoporosis and prevention of fracture].
    Nakamura T
    Nihon Rinsho; 2009 May; 67(5):903-8. PubMed ID: 19432107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Calcium pros and cons: long term use of bisphosphonates. Bisphosphonates should be used for postmenopausal osteoporosis for a long term].
    Soen S
    Clin Calcium; 2011 Oct; 21(10):1543-6. PubMed ID: 21960242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New development in bisphosphonate treatment. Bisphosphonates for the treatment of glucocorticoid-induced osteoporosis].
    Soen S
    Clin Calcium; 2009 Jan; 19(1):44-53. PubMed ID: 19122264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duration of treatment for osteoporosis.
    Idolazzi L; Fassio A; Gatti D; Tamanini S; Viapiana O; Rossini M; Adami S
    Reumatismo; 2013 Mar; 65(1):22-35. PubMed ID: 23550257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of SERMs on bone health. Discrimination of SERMs from bisphosphonates in the treatment of postmenopausal osteoporosis].
    Iwamoto J
    Clin Calcium; 2010 Mar; 20(3):396-407. PubMed ID: 20190370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment goals of osteoporosis].
    Hosoi T
    Clin Calcium; 2014 Mar; 24(3):385-9. PubMed ID: 24576935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Biochemical markers of bone turnover. New aspect. Biochemical markers of bone turnover in long term treatment with bisphosphonate].
    Asano S; Suzuki A; Itoh M
    Clin Calcium; 2009 Aug; 19(8):1179-85. PubMed ID: 19638702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New development in bisphosphonate treatment. Review of effect on bone metabolism by minodronic acid in primary osteoporosis].
    Fukunaga M
    Clin Calcium; 2009 Jan; 19(1):63-73. PubMed ID: 19122266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates.
    Rietbrock S; Olson M; van Staa TP
    QJM; 2009 Jan; 102(1):35-42. PubMed ID: 18842684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bisphosphonates for osteoporosis].
    Narusawa K; Nakamura T
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():311-5. PubMed ID: 18161123
    [No Abstract]   [Full Text] [Related]  

  • 19. [Drug therapy for prevention of falls and fractures].
    Ringe JD
    Med Klin (Munich); 2006 Jun; 101 Suppl 1():1-5. PubMed ID: 16826362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Anti-osteoporosis drugs based on the guidelines for the Prevention and Treatment of Osteoporosis (2011 edition) ].
    Ono K; Ohashi S; Tanaka S
    Clin Calcium; 2014 Mar; 24(3):401-6. PubMed ID: 24576937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.